Keir LS. Shiga toxin associated hemolytic uremic syndrome. Hematol Oncol Clin North Am. 2015 Jun. 29 (3):525-39. [QxMD MEDLINE Link].
Conway EM. HUS and the case for complement. Blood. 2015 Oct 29. 126 (18):2085-90. [QxMD MEDLINE Link].
Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatr Clin North Am. 2018 Jun. 65 (3):509-525. [QxMD MEDLINE Link].
Siegler R, Oakes R. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr Opin Pediatr. 2005 Apr. 17(2):200-4. [QxMD MEDLINE Link].
Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hamolytisch uramische syndrome: Bilaterale Nierenridennekrosen bei akuten erworbenen hamolytischen Anamien. Schweiz Med Wochenschr. 1955. 85:905-909. [Full Text].
Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel). 2020 Jan 21. 12 (2):[QxMD MEDLINE Link]. [Full Text].
Kaper JB, O'Brien AD. Overview and Historical Perspectives. Microbiol Spectr. 2014 Dec. 2 (6):[QxMD MEDLINE Link]. [Full Text].
Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998 Nov 26. 339(22):1578-84. [QxMD MEDLINE Link]. [Full Text].
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998 Nov 26. 339(22):1585-94. [QxMD MEDLINE Link]. [Full Text].
George JN. ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome. Curr Hematol Rep. 2005 May. 4(3):167-9. [QxMD MEDLINE Link].
Haspel RL, Jarolím P. The "cutting" edge: von Willebrand factor-cleaving protease activity in thrombotic microangiopathies. Transfus Apher Sci. 2005 Apr. 32(2):177-84. [QxMD MEDLINE Link].
Blackall DP, Marques MB. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. Am J Clin Pathol. 2004 Jun. 121 suppl:S81-8. [QxMD MEDLINE Link].
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005 Mar 19-25. 365(9464):1073-86. [QxMD MEDLINE Link].
Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011 Nov 10. 365(19):1771-80. [QxMD MEDLINE Link].
Saad AF, Roman J, Wyble A, Pacheco LD. Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome. AJP Rep. 2016 Mar. 6 (1):e125-8. [QxMD MEDLINE Link]. [Full Text].
Meinel C, Spartà G, Dahse HM, Hörhold F, König R, Westermann M, et al. Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells. J Infect Dis. 2018 Jan 17. 217 (3):358-370. [QxMD MEDLINE Link]. [Full Text].
Riesbeck K. Hemolytic Uremic Syndrome Associated With Pneumococci in Children-An Elusive Mystery Now Explained?. J Infect Dis. 2018 Jan 17. 217 (3):341-343. [QxMD MEDLINE Link]. [Full Text].
Caprioli J, Bettinaglio P, Zipfel PF, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol. 2001 Feb. 12(2):297-307. [QxMD MEDLINE Link]. [Full Text].
Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L, Loirat C, et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet. 2005 Nov. 42(11):852-6. [QxMD MEDLINE Link]. [Full Text].
Edey MM, Mead PA, Saunders RE, et al. Association of a factor H mutation with hemolytic uremic syndrome following a diarrheal illness. Am J Kidney Dis. 2008 Mar. 51(3):487-90. [QxMD MEDLINE Link].
Lapeyraque AL, Wagner E, Phan V, et al. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol. 2008 Aug. 23(8):1363-6. [QxMD MEDLINE Link].
Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med. 2001 Dec 18. 135(12):1047-51. [QxMD MEDLINE Link].
Adams DA, Thomas KR, Jajosky RA, Foster L, Baroi G, Sharp P, et al. Summary of Notifiable Infectious Diseases and Conditions - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017 Aug 11. 64 (53):1-143. [QxMD MEDLINE Link]. [Full Text].
Schuppner R, Maehlmann J, Dirks M, Worthmann H, Tryc AB, Sandorski K, et al. Neurological Sequelae in Adults After E coli O104: H4 Infection-Induced Hemolytic-Uremic Syndrome. Medicine (Baltimore). 2016 Feb. 95 (6):e2337. [QxMD MEDLINE Link].
Ardissino G, Tel F, Testa S, Paglialonga F, Longhi S, Martelli L, et al. A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: data from the ItalKid-HUS network. Eur J Pediatr. 2018 Nov. 177 (11):1667-1674. [QxMD MEDLINE Link].
Alconcher LF, Coccia PA, Suarez ADC, et al. Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol. 2018 Oct. 33 (10):1791-1798. [QxMD MEDLINE Link].
Santos AH Jr, Casey MJ, Wen X, Zendejas I, Faldu C, Rehman S, et al. Outcome of kidney transplants for adults with hemolytic uremic syndrome in the U.S.: a ten-year database analysis. Ann Transplant. 2014 Jul 21. 19:353-61. [QxMD MEDLINE Link].
Walsh PR, Johnson S, Brocklebank V, Salvatore J, Christian M, Kavanagh D. Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome. Am J Kidney Dis. 2018 Feb. 71 (2):287-290. [QxMD MEDLINE Link].
Burns ER, Lou Y, Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol. 2004 Jan. 75(1):18-21. [QxMD MEDLINE Link].
Karnisova L, Hradsky O, Blahova K, Fencl F, Dolezel Z, Zaoral T, et al. Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr. 2018 Dec. 177 (12):1837-1844. [QxMD MEDLINE Link].
McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence Shiga toxin production. Antimicrob Agents Chemother. 2010 Sept. 54(9):3790-3798.
Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev. 2009 Jan 21. CD003595. [QxMD MEDLINE Link].
FDA approves Soliris for rare pediatric blood disorder. U.S. Food and Drug Administration. Available at https://wayback.archive-it.org/7993/20170114063405/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm272990.htm. September 23, 2011; Accessed: December 13, 2018.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 Jun 6. 368(23):2169-81. [QxMD MEDLINE Link]. [Full Text].
Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. Am J Kidney Dis. 2016 Mar 16. [QxMD MEDLINE Link].
Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016 Mar. 89 (3):701-11. [QxMD MEDLINE Link]. [Full Text].
Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021 May 6. 137 (18):2438-2449. [QxMD MEDLINE Link].
Ultomiris (ravulizumab) [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc. October 2019. Available at [Full Text].
Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29. 342(26):1930-6. [QxMD MEDLINE Link]. [Full Text].
Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep. 2017 Jun 1. 9 (2):7053. [QxMD MEDLINE Link]. [Full Text].
Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, et al. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clin Proc. 2018 Oct. 93 (10):1351-1362. [QxMD MEDLINE Link].